Soleno Therapeutics(SLNO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SLNO Soleno Therapeutics

休市中 04-24 16:00:00 EDT

52.72

-0.11

-0.21%

盘后52.72

+0.000.00%

19:07 EDT

最高52.88	最低52.70	成交量328.20万
今开52.85	昨收52.83	日振幅0.34%
总市值27.22亿	流通市值23.66亿	总股本5,162万
成交额1.73亿	换手率7.31%	流通股本4,487万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"SLNO","market":"US","secType":"STK","nameCN":"Soleno Therapeutics","latestPrice":52.72,"timestamp":1777060800000,"preClose":52.83,"halted":0,"volume":3281970,"hourTrading":{"tag":"盘后","latestPrice":52.72,"preClose":52.72,"latestTime":"19:07 EDT","volume":33078,"amount":1743869.18,"timestamp":1777072025212,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.0020821502933938943,"floatShares":44870900,"shares":51624384,"eps":0.39,"marketStatus":"休市中","change":-0.11,"latestTime":"04-24 16:00:00 EDT","open":52.845,"high":52.88,"low":52.7,"amount":173139090.04731,"amplitude":0.003407,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.39,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1777276800000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":52.83,"preHourTrading":{"tag":"盘前","latestPrice":52.85,"preClose":52.83,"latestTime":"09:29 EDT","volume":1729,"amount":91400.31719,"timestamp":1777037399999,"change":0.02,"changeRate":0.000379,"amplitude":0.002839},"postHourTrading":{"tag":"盘后","latestPrice":52.72,"preClose":52.72,"latestTime":"19:07 EDT","volume":33078,"amount":1743869.18,"timestamp":1777072025212,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.3637972016429531,"impliedVol":0.2161,"impliedVolPercentile":0.004},"requestUrl":"/m/hq/s/SLNO","defaultTab":"news","newsList":[{"id":"1156303425","title":"Piper Sandler将Soleno Therapeutics评级从增持下调至中性，目标价从145美元大幅削减至53美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1156303425","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156303425?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:25","pubTimestamp":1775564715,"startTime":"0","endTime":"0","summary":"Piper Sandler宣布，将生物制药公司Soleno Therapeutics的股票评级从\"增持\"下调至\"中性\"。同时，该机构将其目标股价从145美元大幅下调至53美元，显示出对公司短期前景的谨慎态度。此次评级和目标价的双重调整，可能影响市场对该股的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLNO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156119105","title":"Soleno Therapeutics撤回Viokas欧洲上市许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1156119105","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156119105?lang=zh_cn&edition=full","pubTime":"2026-04-07 19:00","pubTimestamp":1775559638,"startTime":"0","endTime":"0","summary":"Soleno Therapeutics公司近日向美国证券交易委员会提交文件，宣布正式撤回其药物Viokas在欧洲地区的上市许可申请。这一决定标志着该药物在欧洲市场的商业化进程暂时中止。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLNO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144823700","title":"期权大单 | 特斯拉遭摩根大通看空，看跌期权活跃；美光看涨期权活跃，SLNO期权成交量放大32倍","url":"https://stock-news.laohu8.com/highlight/detail?id=1144823700","media":"老虎资讯综合","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144823700?lang=zh_cn&edition=full","pubTime":"2026-04-07 14:18","pubTimestamp":1775542736,"startTime":"0","endTime":"0","summary":"期权市场总成交量44,426,493张合约，其中看涨期权占比52%。消息方面：小摩绩前唱空特斯拉，警告股价恐暴跌60%。Brinkman及其团队目前预计特斯拉第一季度每股收益为0.30美元，低于此前预期的0.43美元，而市场普遍预期为0.38美元。6月18日到期的55美元的行权看涨期权交易量特别高，共有18,880份合约交易。","market":"us","thumbnail":"https://static.tigerbbs.com/76824cd4c5b97eaacdaab63d96995a28","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/76824cd4c5b97eaacdaab63d96995a28"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"e8d061d547be066b23a2237c75723a2b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMC","MU","SLNO","TSLA"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2625601273","title":"美股成交额TOP 20 | 特斯拉跌超2%，遭摩根大通看空；存储概念股普涨，美光科技、闪迪涨超3%；Soleno飙升逾32%，获29亿美元溢价收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2625601273","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625601273?lang=zh_cn&edition=full","pubTime":"2026-04-07 06:45","pubTimestamp":1775515500,"startTime":"0","endTime":"0","summary":"周一美股成交额第1名特斯拉收跌2.15%，成交272.32亿美元。特斯拉再次成为摩根大通的关注焦点，该行坚持认为该股仍有显著下行空间。摩根大通坚持其对2026年12月145美元的目标价，这意味着该行预测特斯拉股价较当前水平约有60%的下行空间。事实上，尽管自2022年6月交付量达到峰值以来，特斯拉的增长已远不如前，但目前股价仍比当时高出50%以上。KeyBanc预计美光股价有60%上行空间。","market":"us","thumbnail":"https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"9b98e133a29ff8ddb0107f2ebb871b53","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-07/doc-inhtrcpr7525414.shtml","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["TSLA","MU","SLNO"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2625693674","title":"Neurocrine斥资29亿美元收购Soleno，进军代谢疾病领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2625693674","media":"智通财经网","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625693674?lang=zh_cn&edition=full","pubTime":"2026-04-07 06:05","pubTimestamp":1775513144,"startTime":"0","endTime":"0","summary":"Neurocrine Biosciences周一表示，将以现金29亿美元收购罕见病药企Soleno Therapeutics，标志着这家专注神经科学领域的制药公司向代谢疾病领域扩张。","market":"fut","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425299.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Neurocrine斥资29亿美元收购Soleno，进军代谢疾病领域","news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU0320765992.SGD","LU2065170008.USD","LU2324357040.USD","LU0823416689.USD","NBIX","SLNO","LU2065169927.USD","LU2065171402.SGD","LU2065171311.SGD","BK4139","LU0154245673.USD","LU0154245756.USD","LU0109394709.USD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625567284","title":"SLNO因收购传闻跳涨，交易消息提振个股","url":"https://stock-news.laohu8.com/highlight/detail?id=2625567284","media":"环球市场播报","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625567284?lang=zh_cn&edition=full","pubTime":"2026-04-06 21:46","pubTimestamp":1775483160,"startTime":"0","endTime":"0","summary":"Soleno Therapeutics在周一早盘成为市场焦点，因交易谈判推动该股在盘前交易中大幅上涨26%。Twilio TWLO上涨约3%，此前杰富瑞将该股评级上调至“买入”，并设定了160美元的目标价，指出其在语音AI领域定位更加强劲且基本面正在改善。Netflix也上涨约2%，此前高盛将其评级上调至“买入”，目标价为120美元，强调了更好的增长可见性、利润率扩张以及股票回购的潜力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"d77fbd5412928557c10e0692aaf5dc46","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-06/doc-inhtqnrx7835057.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","SLNO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146320564","title":"特定条件下交易终止时 Soleno 将向 Neurocrine 支付9.53亿美元解约金","url":"https://stock-news.laohu8.com/highlight/detail?id=1146320564","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146320564?lang=zh_cn&edition=full","pubTime":"2026-04-06 19:39","pubTimestamp":1775475553,"startTime":"0","endTime":"0","summary":"根据最新披露的协议条款，若此次并购交易因特定情形被迫终止，Soleno Therapeutics（SLNO）需向Neurocrine Biosciences（NBIX）支付高达9.53亿美元的解约费用。这一条款为交易设置了明确的风险对冲机制。\n该金额的设定反映出双方对交易价值的共同认知，同时也为可能出现的意外情况提供了契约保障。分析师指出，此类终止费条款在生物医药行业并购中较为常见，既能保护收购方利益，又体现了卖方的交易诚意。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"d77fbd5412928557c10e0692aaf5dc46","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU2065170008.USD","LU2065171402.SGD","BK4139","LU0154245756.USD","LU2324357040.USD","SLNO","LU0154245673.USD","LU0320765992.SGD","LU2065171311.SGD","LU2065169927.USD","NBIX","LU0823416689.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197470067","title":"Soleno Therapeutics股价盘前飙升30%，传神经分泌生物科学接近达成25亿美元收购协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1197470067","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197470067?lang=zh_cn&edition=full","pubTime":"2026-04-06 16:35","pubTimestamp":1775464514,"startTime":"0","endTime":"0","summary":"有报道称神经分泌生物科学（Neurocrine Biosciences）即将以约25亿美元的价格收购Soleno Therapeutics，这一消息推动后者股价在盘前交易中大幅上涨30%。市场对这笔潜在交易反应热烈，反映出投资者对两家公司战略整合前景的积极预期。\n此次收购若成功落地，将成为神经科学领域近年来的重要并购案例。神经分泌生物科学通过整合Soleno Therapeutics的研发管线，有望强化其在中枢神经系统治疗领域的布局。盘前交易量的显著增长，也体现出资本市场对行业资源整合的高度关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"d77fbd5412928557c10e0692aaf5dc46","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171402.SGD","LU0154245673.USD","LU0109394709.USD","LU0320765992.SGD","LU2065169927.USD","LU0823416689.USD","NBIX","BK4139","LU2065171311.SGD","SLNO","LU2324357040.USD","LU0889565916.HKD","LU2065170008.USD","LU0154245756.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134553390","title":"异动解读 | 传Neurocrine逾25亿美元收购，Soleno Therapeutics盘前大涨25.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=1134553390","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134553390?lang=zh_cn&edition=full","pubTime":"2026-04-06 16:04","pubTimestamp":1775462696,"startTime":"0","endTime":"0","summary":"Soleno Therapeutics今日盘前股价大幅上涨25.35%，市场表现异常活跃。消息面上，据《金融时报》等多家媒体报道，制药商Neurocrine Biosciences正接近以超过25亿美元的价格收购这家罕见遗传学制药商，报道指出潜在的交易价值可能在每股50美元左右，显著高于Soleno Therapeutics之前的收盘价，为股价带来了强劲的上涨动力。Soleno Therapeutics的核心产品是用于治疗普拉德-威利综合症的Vykat XR药物，而收购方Neurocrine Biosciences市值约132亿美元，拥有多款已获批药物，市场分析认为此次收购若能达成，将显著提升Soleno Therapeutics的价值。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"d77fbd5412928557c10e0692aaf5dc46","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SLNO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119884792","title":"异动解读 | 传Neurocrine逾25亿美元收购Soleno，后者夜盘飙涨20.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=1119884792","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119884792?lang=zh_cn&edition=full","pubTime":"2026-04-06 15:36","pubTimestamp":1775460999,"startTime":"0","endTime":"0","summary":"Soleno Therapeutics在今日夜盘交易中大幅上涨20.49%，市场表现异常活跃。消息面上，据《金融时报》等多家媒体报道，制药商Neurocrine Biosciences正接近以超过25亿美元的价格收购这家罕见遗传学制药商。而收购方Neurocrine Biosciences市值约132亿美元，拥有包括Ingrezza在内的多款已获批药物。市场分析认为，此次收购若能达成，将显著提升Soleno Therapeutics的价值，并可能改变其在罕见病治疗领域的竞争格局。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"d77fbd5412928557c10e0692aaf5dc46","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SLNO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192207553","title":"Neurocrine Biosciences据报接近以逾25亿美元收购Soleno Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=1192207553","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192207553?lang=zh_cn&edition=full","pubTime":"2026-04-06 11:24","pubTimestamp":1775445893,"startTime":"0","endTime":"0","summary":"据 Financial Times 报道，制药公司  $神经分泌生物科学(NBIX)$  正接近达成一项超过25亿美元的收购交易，目标为  $Soleno Therapeutics(SLNO)$ 。受消息影响，  $神经分泌生物科学(NBIX)$  夜盘跌3%， $Soleno Therapeutics(SLNO)$ 夜盘飙20%。","market":"hk","thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"d77fbd5412928557c10e0692aaf5dc46","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Neurocrine Biosciences据报接近以逾25亿美元收购Soleno Therapeutics","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLNO","NBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181753293","title":"Soleno Therapeutics宣布James Mackaness荣退，任命Jennifer Fulk为新任首席财务官","url":"https://stock-news.laohu8.com/highlight/detail?id=1181753293","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181753293?lang=zh_cn&edition=full","pubTime":"2026-02-26 21:05","pubTimestamp":1772111137,"startTime":"0","endTime":"0","summary":"Soleno Therapeutics（简称SLNO）近日宣布，公司首席财务官James Mackaness已正式退休。与此同时，Jennifer Fulk被任命为新任首席财务官，即刻接任相关职责。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLNO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138248088","title":"Soleno Therapeutics任命Jennifer Fulk为首席财务官 2026年3月2日生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1138248088","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138248088?lang=zh_cn&edition=full","pubTime":"2026-02-26 19:12","pubTimestamp":1772104321,"startTime":"0","endTime":"0","summary":"生物制药公司Soleno Therapeutics近日宣布一项重要人事任命。根据2月25日提交至美国证券交易委员会（SEC）的文件显示，公司已正式任命Jennifer Fulk担任首席财务官（CFO）一职，该任命将于2026年3月2日正式生效。\n此次高管变动标志着Soleno Therapeutics在战略布局上的重要一步。Jennifer Fulk在财务管理领域拥有丰富经验，预计将为公司带来新的发展动能。随着新任首席财务官的到位，Soleno Therapeutics有望进一步加强其财务运营体系，为未来业务拓展提供有力支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLNO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128132855","title":"财报前瞻 ｜Soleno Therapeutics营收预计8,854.76万美元，机构观点偏看多","url":"https://stock-news.laohu8.com/highlight/detail?id=1128132855","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128132855?lang=zh_cn&edition=full","pubTime":"2026-02-18 13:06","pubTimestamp":1771391219,"startTime":"0","endTime":"0","summary":"Soleno Therapeutics将于2026年02月25日盘后发布最新季度财报，市场关注营收动能与盈利质量的延续性及指引与一致预期的差异。市场一致预期本季度调整后每股收益为0.71，同比增长161.63%；息税前利润为3,641.53万美元，同比增长174.02%；营收预计为8,854.76万美元，目前缺少可靠同比口径，毛利率与净利率亦暂无覆盖的预测数据。公司上季度营收6,601.80万美元，毛利率98.27%，归属于母公司股东的净利润2,601.30万美元，净利率39.40%，调整后每股收益0.47，同比增长125.68%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻 ｜Soleno Therapeutics营收预计8,854.76万美元，机构观点偏看多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLNO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183801152","title":"异动解读 | Soleno Therapeutics盘中大跌5.06%，因贝尔德下调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1183801152","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183801152?lang=zh_cn&edition=full","pubTime":"2026-01-13 23:18","pubTimestamp":1768317517,"startTime":"0","endTime":"0","summary":"Soleno Therapeutics（股票代码：SLNO）今日盘中股价大跌5.06%，引起市场关注。消息面上，贝尔德（Baird）分析师将其目标价从121美元下调至107美元。这一调整可能反映了分析师对公司未来业绩或市场前景的谨慎态度，从而影响了投资者的信心，导致股价下跌。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SLNO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108532687","title":"Soleno Therapeutics公司预计2025年第二季度起Vykat XR美国销售净收入将达1.89亿至1.91亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1108532687","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108532687?lang=zh_cn&edition=full","pubTime":"2026-01-12 20:06","pubTimestamp":1768219605,"startTime":"0","endTime":"0","summary":"Soleno Therapeutics公司近日发布预测，其核心产品Vykat XR自2025年第二季度在美国市场上市后，全年净销售收入预计将落在1.89亿美元至1.91亿美元的区间内。这一业绩展望凸显了公司对该创新疗法商业前景的强劲信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLNO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602630313","title":"Soleno Therapeutics, Inc.盘中异动 股价大跌5.09%报43.19美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2602630313","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602630313?lang=zh_cn&edition=full","pubTime":"2026-01-10 01:14","pubTimestamp":1767978845,"startTime":"0","endTime":"0","summary":"北京时间2026年01月10日01时14分，Soleno Therapeutics, Inc.股票出现异动，股价大幅跳水5.09%。Soleno Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.59%。其相关个股中，Novabay Pharmaceuticals, Inc.、Revolution Medicines Inc C/Wts 17/12/2026 、Akoustis Technologies Inc涨幅较大，Aptevo Therapeutics Inc.、Pmgc Holdings Inc.、Ibio, Inc.较为活跃，换手率分别为630.77%、72.24%、44.53%，振幅较大的相关个股有Novabay Pharmaceuticals, Inc.、Akoustis Technologies Inc、Revolution Medicines Inc C/Wts 17/12/2026 ，振幅分别为50.74%、36.28%、35.11%。Soleno Therapeutics, Inc.公司简介：Soleno Therapeutics Inc 是一家生物制药公司，开发用于治疗罕见病的新型疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260110011405a7083391&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260110011405a7083391&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","SLNO","LENZ","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147237720","title":"新闻稿：Soleno Therapeutics宣布董事会成员William G. Harris的去世","url":"https://stock-news.laohu8.com/highlight/detail?id=1147237720","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147237720?lang=zh_cn&edition=full","pubTime":"2025-12-04 05:08","pubTimestamp":1764796080,"startTime":"0","endTime":"0","summary":"加州红木城，2025年12月3日— Soleno Therapeutics, Inc.是一家专注于开发治疗罕见疾病的新型药物的生物制药公司，今天遗憾地宣布，自2014年6月以来担任董事会重要成员的William G. \"Bill\" Harris已去世。“我认识Bill很多年，一直视他为一个具有正直品质的人，具备务实精神和真正帮助他人的愿望，” Soleno Therapeutics的首席执行官兼董事会主席Anish Bhatnagar博士表示。Soleno预计长期担任董事会及审计委员会成员的Andrew Sinclair将接任审计委员会主席一职。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4585","BK4555","BK4588","BK4604","TM","SLNO","BK4139","BK4099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123133830","title":"Soleno Therapeutics宣布进入1亿美元的加速回购协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1123133830","media":"投资观察","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123133830?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:22","pubTimestamp":1763572953,"startTime":"0","endTime":"0","summary":"11月11日 - Soleno Therapeutics Inc宣布已签署一项1亿美元的加速回购协议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLNO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162270798","title":"Soleno Therapeutics股价在盘前上涨8.4%，因公司宣布进入1亿加元的加速股票回购协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1162270798","media":"美股速递","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162270798?lang=zh_cn&edition=full","pubTime":"2025-11-11 21:10","pubTimestamp":1762866612,"startTime":"0","endTime":"0","summary":"Soleno Therapeutics股价在盘前上涨8.4%，因公司宣布进入1亿加元的加速股票回购协议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLNO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.soleno.life","stockEarnings":[{"period":"1week","weight":-0.0011},{"period":"1month","weight":0.6558},{"period":"3month","weight":0.2446},{"period":"6month","weight":-0.1786},{"period":"1year","weight":-0.2898},{"period":"ytd","weight":0.1387}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.087},{"period":"3month","weight":0.0359},{"period":"6month","weight":0.0542},{"period":"1year","weight":0.3059},{"period":"ytd","weight":0.047}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Soleno Therapeutics, Inc.于1999年8月25日在特拉华州成立。该公司专注于治疗罕见病的新型疗法的开发和商业化。该公司的主要候选药物DCCR（二氮嗪胆碱）缓释片是一种有效的ATP敏感钾（KATP）通道激活剂。","yearOnYearQuotes":[{"month":1,"riseRate":0.583333,"avgChangeRate":0.026118},{"month":2,"riseRate":0.333333,"avgChangeRate":0.234502},{"month":3,"riseRate":0.583333,"avgChangeRate":-0.004811},{"month":4,"riseRate":0.5,"avgChangeRate":0.09394},{"month":5,"riseRate":0.545455,"avgChangeRate":0.074125},{"month":6,"riseRate":0.363636,"avgChangeRate":-0.071619},{"month":7,"riseRate":0.363636,"avgChangeRate":-0.051924},{"month":8,"riseRate":0.545455,"avgChangeRate":-0.014863},{"month":9,"riseRate":0.454545,"avgChangeRate":0.409781},{"month":10,"riseRate":0.272727,"avgChangeRate":-0.115533},{"month":11,"riseRate":0.454545,"avgChangeRate":-0.012609},{"month":12,"riseRate":0.333333,"avgChangeRate":0.051862}],"exchange":"NASDAQ","name":"Soleno Therapeutics","nameEN":"Soleno Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Soleno Therapeutics(SLNO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Soleno Therapeutics(SLNO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Soleno Therapeutics,SLNO,Soleno Therapeutics股票,Soleno Therapeutics股票老虎,Soleno Therapeutics股票老虎国际,Soleno Therapeutics行情,Soleno Therapeutics股票行情,Soleno Therapeutics股价,Soleno Therapeutics股市,Soleno Therapeutics股票价格,Soleno Therapeutics股票交易,Soleno Therapeutics股票购买,Soleno Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Soleno Therapeutics(SLNO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Soleno Therapeutics(SLNO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}